a Department of Surgery , VU University Medical Center , Amsterdam , the Netherlands.
b Department of Medical Oncology , VU University Medical Center , Amsterdam , the Netherlands.
Expert Rev Mol Diagn. 2015;15(12):1525-9. doi: 10.1586/14737159.2015.1112273. Epub 2015 Nov 15.
There is an urgent need for novel and reliable biomarkers for the diagnosis and prognostication of pancreatic ductal adenocarcinoma (PDAC). Circulating microRNAs (miRNAs) have been extensively profiled in PDAC blood samples, but few studies have performed adequate validation of candidate markers. The evaluated study by Xu et al. investigated pre-operative plasma miRNAs from PDAC patients over three phases and three surgical centers. They revealed miR-486-5p and miR-938 were able to discriminate PDAC patients from healthy controls and those with chronic pancreatitis. The diagnostic ability of miR-486-5p for identifying PDAC from healthy controls was comparable to that of CA 19-9. This study provides further evidence for the use of blood-based miRNAs as diagnostic biomarkers in PDAC. However, as these have not been identified in previous studies these require further validation and methodology needs to be standardized if these are ever to be used in the clinic.
目前迫切需要新的、可靠的生物标志物来诊断和预测胰腺导管腺癌 (PDAC)。循环 microRNAs (miRNAs) 在 PDAC 血液样本中已被广泛研究，但很少有研究对候选标志物进行充分的验证。徐等人评估的研究调查了三个阶段和三个手术中心的 PDAC 患者术前血浆中的 miRNAs。他们发现 miR-486-5p 和 miR-938 能够区分 PDAC 患者与健康对照者和慢性胰腺炎患者。miR-486-5p 识别 PDAC 患者与健康对照者的诊断能力与 CA 19-9 相当。这项研究为血液中 miRNAs 作为 PDAC 诊断生物标志物的应用提供了进一步的证据。然而，由于这些 miRNA 尚未在前瞻性研究中得到证实，因此需要进一步验证，如果要将其用于临床，还需要标准化方法。
